GlassScriptPhysician profile
Nicole Mezo
NPI 1861702441
$4,388.84
in general payments reported to CMS, 2019-2025
22 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $369 · 2023: $806 · 2024: $1,344 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.74 |
| Education | $108.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $655.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $644.06 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $587.21 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Glaxosmithkline, LLC. | $582.83 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $357.02 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Pfizer INC. | $188.34 | 2021-2025 | |
| Abbvie INC. | $173.49 | 2023-2025 | |
| Grifols USA, LLC | $169.28 | 2021-2023 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $135.16 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $121.68 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $111.48 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $108.03 | 2021-2025 | |
| Amgen INC. | $101.48 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Kaleo, INC. | $90.27 | 2022-2024 | Auvi-Q |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $76.94 | 2025 | Dawnzera |
| Leo Pharma INC. | $50.66 | 2024-2025 | Adbry |
| Genentech USA, INC. | $47.54 | 2021-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $30.43 | 2022-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $23.87 | 2025 | Neffy |
| Pharming Healthcare, INC. | $20.05 | 2022 | |
| Organon LLC | $13.23 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Mezo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.